This crossover trial (n=24) investigates the acute effects of R- and S-MDMA compared to racemic MDMA and placebo in healthy subjects.
Randomised, double-blind, triple-masked, five-period crossover in healthy volunteers comparing 125 mg racemic MDMA, 125 mg S-MDMA, 125 mg R-MDMA, 250 mg R-MDMA, and placebo.
Primary aim is basic science: to characterise acute subjective, physiological and neuroendocrine differences between enantiomers and racemate; participants abstain from psychoactives and follow protocol restrictions.
Racemic MDMA 125 mg, single oral dose (one period of the crossover).
Enantiomeric S-MDMA 125 mg, single oral dose.
S-enantiomer
Enantiomeric R-MDMA 125 mg, single oral dose.
R-enantiomer
Enantiomeric R-MDMA 250 mg, single oral dose.
Higher R-enantiomer dose
Placebo (mannitol) single oral dose.
Mannitol placebo